Review





Similar Products

mutational profiling map fragmentation buffer  (Zymo Research)
95
Zymo Research mutational profiling map fragmentation buffer
Mutational Profiling Map Fragmentation Buffer, supplied by Zymo Research, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mutational profiling map fragmentation buffer/product/Zymo Research
Average 95 stars, based on 1 article reviews
mutational profiling map fragmentation buffer - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
tumor mutational profiles  (Caris Life Sciences)
86
Caris Life Sciences tumor mutational profiles
(A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
Tumor Mutational Profiles, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tumor mutational profiles/product/Caris Life Sciences
Average 86 stars, based on 1 article reviews
tumor mutational profiles - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
human cancer cell line expression profiles and somatic mutation data  (Broad Institute Inc)
90
Broad Institute Inc human cancer cell line expression profiles and somatic mutation data
(A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
Human Cancer Cell Line Expression Profiles And Somatic Mutation Data, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cancer cell line expression profiles and somatic mutation data/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
human cancer cell line expression profiles and somatic mutation data - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
somatic mutation profiles  (Illumina Inc)
90
Illumina Inc somatic mutation profiles
(A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
Somatic Mutation Profiles, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/somatic mutation profiles/product/Illumina Inc
Average 90 stars, based on 1 article reviews
somatic mutation profiles - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes  (Bio-Rad)
99
Bio-Rad oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes
(A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
Oncocompasstm Target Cancer Mutation Profiling Liquid Kit Burning Rock Biotech N A Ddpcrtm Supermix For Probes, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes/product/Bio-Rad
Average 99 stars, based on 1 article reviews
oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
somatic mutation data and expression profile data of human cancer cell lines (ccls)  (Broad Institute Inc)
90
Broad Institute Inc somatic mutation data and expression profile data of human cancer cell lines (ccls)
(A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
Somatic Mutation Data And Expression Profile Data Of Human Cancer Cell Lines (Ccls), supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/somatic mutation data and expression profile data of human cancer cell lines (ccls)/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
somatic mutation data and expression profile data of human cancer cell lines (ccls) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
rt-pcr detecting specific spike mutation profiles allplex sars-cov-2 variants i assay  (Seegene Technologies)
90
Seegene Technologies rt-pcr detecting specific spike mutation profiles allplex sars-cov-2 variants i assay
(A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
Rt Pcr Detecting Specific Spike Mutation Profiles Allplex Sars Cov 2 Variants I Assay, supplied by Seegene Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rt-pcr detecting specific spike mutation profiles allplex sars-cov-2 variants i assay/product/Seegene Technologies
Average 90 stars, based on 1 article reviews
rt-pcr detecting specific spike mutation profiles allplex sars-cov-2 variants i assay - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mutation profiles  (BioResource International Inc)
90
BioResource International Inc mutation profiles
(A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
Mutation Profiles, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mutation profiles/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
mutation profiles - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
tcga mutation profiles  (Broad Institute Inc)
90
Broad Institute Inc tcga mutation profiles
(A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
Tcga Mutation Profiles, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tcga mutation profiles/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
tcga mutation profiles - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


(A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).

Journal: Cancer Medicine

Article Title: Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos

doi: 10.1002/cam4.71216

Figure Lengend Snippet: (A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).

Article Snippet: We examined tumor mutational profiles of GC from 106 PRH between 2015 and 2022 (provided by CARIS Life Sciences and the Precision Oncology Alliance).

Techniques:

Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).

Journal: Cancer Medicine

Article Title: Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos

doi: 10.1002/cam4.71216

Figure Lengend Snippet: Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).

Article Snippet: We examined tumor mutational profiles of GC from 106 PRH between 2015 and 2022 (provided by CARIS Life Sciences and the Precision Oncology Alliance).

Techniques: Protein-Protein interactions, Amplification